431 related articles for article (PubMed ID: 11818480)
21. [Chronic myeloid leukemia: "archetype" of the impact of targeted therapies].
Nasr R; Bazarbachi A
Pathol Biol (Paris); 2012 Aug; 60(4):239-45. PubMed ID: 22743097
[TBL] [Abstract][Full Text] [Related]
22. Specific targeted therapy of chronic myelogenous leukemia with imatinib.
Deininger MW; Druker BJ
Pharmacol Rev; 2003 Sep; 55(3):401-23. PubMed ID: 12869662
[TBL] [Abstract][Full Text] [Related]
23. Applying the discovery of the Philadelphia chromosome.
Sherbenou DW; Druker BJ
J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
[TBL] [Abstract][Full Text] [Related]
24. [Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].
Molnár L; Losonczy H
Orv Hetil; 2002 Oct; 143(42):2379-84. PubMed ID: 12440260
[TBL] [Abstract][Full Text] [Related]
25. [A new drug in the therapy of chronic myeloid leukemia: ST1571].
Salesi N; Bossone G; Della Longa G; Di Cocco B
Minerva Med; 2003 Apr; 94(2):71-6. PubMed ID: 12858155
[TBL] [Abstract][Full Text] [Related]
26. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
27. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
28. [Chronic myeloid leukemia as a model for modern noncytostatic therapy of malignant diseases. From Virchow to STI 571].
Mayer J
Vnitr Lek; 2002 Jan; 48(1):45-9. PubMed ID: 11852587
[TBL] [Abstract][Full Text] [Related]
29. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
30. [Tyrosine kinase inhibitor--hematological malignancies].
Ohno R
Gan To Kagaku Ryoho; 2001 May; 28(5):601-7. PubMed ID: 11383207
[TBL] [Abstract][Full Text] [Related]
31. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
Druker BJ
Oncogene; 2002 Dec; 21(56):8541-6. PubMed ID: 12476300
[No Abstract] [Full Text] [Related]
33. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
[TBL] [Abstract][Full Text] [Related]
34. [Molecular targeting therapy for chronic myelogenous leukemia].
Ono R
Nihon Naika Gakkai Zasshi; 2003 May; 92(5):884-9. PubMed ID: 12808916
[No Abstract] [Full Text] [Related]
35. STI571 as a targeted therapy for CML.
O'Dwyer ME; Mauro MJ; Druker BJ
Cancer Invest; 2003 Jun; 21(3):429-38. PubMed ID: 12901289
[TBL] [Abstract][Full Text] [Related]
36. Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer.
Shah NP; Sawyers CL
Curr Opin Investig Drugs; 2001 Mar; 2(3):422-3. PubMed ID: 11575716
[No Abstract] [Full Text] [Related]
37. Chronic myeloid leukemia--advances in biology and new approaches to treatment.
Goldman JM; Melo JV
N Engl J Med; 2003 Oct; 349(15):1451-64. PubMed ID: 14534339
[No Abstract] [Full Text] [Related]
38. [How I treat...chronic myeloid leukemia].
Hafraoui K; Humblet-Baron S; Baron F; Beguin Y; Fillet G
Rev Med Liege; 2003 Jan; 58(1):7-12. PubMed ID: 12647591
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of chronic myelogenous leukemia with tyrosine kinase inhibitor].
Ohno R
Nihon Rinsho; 2001 Dec; 59(12):2389-94. PubMed ID: 11766344
[TBL] [Abstract][Full Text] [Related]
40. [Changing concept of conventional therapy in chronic myelogenous leukemia].
Ueda R
Rinsho Ketsueki; 2000 Apr; 41(4):268-71. PubMed ID: 10846452
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]